Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient | Zendy

Jori Symons | Zendy; S.F.L. van Lelyveld | Zendy; A. I. M. Hoepelman | Zendy; Petra M. van Ham | Zendy; D. de Jong | Zendy; Amj Wensing | Zendy; Monique Nijhuis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient

Author(s) -

Jori Symons,

S.F.L. van Lelyveld,

A. I. M. Hoepelman,

Petra M. van Ham,

D. de Jong,

Amj Wensing,

Monique Nijhuis

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq535

Subject(s) - maraviroc , tropism , ccr5 receptor antagonist , tissue tropism , virology , cxcr4 , biology , chemokine receptor , chemokine receptor ccr5 , viral replication , virus , receptor , chemokine , human immunodeficiency virus (hiv) , genetics

Maraviroc is the first licensed chemokine co-receptor 5 (CCR5) co-receptor antagonist in clinical practice. It is currently being used in patients harbouring exclusively CCR5-tropic virus. The objective of the study was to investigate the impact of maraviroc on viruses with different co-receptor preferences in a patient with a dual/mixed (D/M) infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research